Autism and Regenerative Medicine: A Mother's Story
- svisser50
- 6 days ago
- 1 min read
We're excited to share real progress and measurable results for our 5-year-old patient, Olivia.
Olivia began IV exosome therapy in July 2025, completing an initial series of six treatments approximately two weeks apart, followed by two additional IV infusions in early 2026.
Olivia began ABA therapy in January 2026 and quickly demonstrated the benefits between autism and regenerative medicine. At her July 2026 re-evaluation, her Vineland-3 scores showed gains across every domain, which measured:
Daily Living Skills: +23 points
Communication: +14 points
Socialization: +14 points
Overall Adaptive Behavior: +13 points
Motor Skills: +4 points
Her family's own reporting reflects progress as well, with a 40% reduction in reported concerns and difficulties from her pre-treatment survey.
Because Olivia has also been receiving ABA therapy, these changes cannot be attributed to any single intervention. What we can celebrate is documented progress across multiple measures.
Shared with permission. Individual results vary. This patient's experience does not establish that exosome therapy caused the reported changes.
